share_log

We Ran A Stock Scan For Earnings Growth And Chengdu Kanghong Pharmaceutical Group (SZSE:002773) Passed With Ease

We Ran A Stock Scan For Earnings Growth And Chengdu Kanghong Pharmaceutical Group (SZSE:002773) Passed With Ease

我们对盈利增长进行了股票筛选,康弘药业 (SZSE:002773) 轻松通过。
Simply Wall St ·  12/12 17:33

It's common for many investors, especially those who are inexperienced, to buy shares in companies with a good story even if these companies are loss-making. But as Peter Lynch said in One Up On Wall Street, 'Long shots almost never pay off.' While a well funded company may sustain losses for years, it will need to generate a profit eventually, or else investors will move on and the company will wither away.

许多投资者,特别是那些缺乏经验的投资者,常常购买那些即使亏损但有好故事的公司的股票。但正如彼得·林奇在《华尔街之狼》中所说,'长期投资几乎从来不会带来回报。'虽然一家公司可以在多年内持续亏损,但最终它需要实现盈利,否则投资者将会转向其他公司,企业也将随之消亡。

So if this idea of high risk and high reward doesn't suit, you might be more interested in profitable, growing companies, like Chengdu Kanghong Pharmaceutical Group (SZSE:002773). While profit isn't the sole metric that should be considered when investing, it's worth recognising businesses that can consistently produce it.

因此,如果这种高风险高回报的想法不适合你,那么你可能会对盈利且持续增长的公司更感兴趣,比如康弘药业(SZSE:002773)。虽然盈利不是投资时应考虑的唯一指标,但值得关注能够持续产生利润的企业。

How Fast Is Chengdu Kanghong Pharmaceutical Group Growing?

康弘药业的增长速度有多快?

The market is a voting machine in the short term, but a weighing machine in the long term, so you'd expect share price to follow earnings per share (EPS) outcomes eventually. Therefore, there are plenty of investors who like to buy shares in companies that are growing EPS. To the delight of shareholders, Chengdu Kanghong Pharmaceutical Group has achieved impressive annual EPS growth of 48%, compound, over the last three years. While that sort of growth rate isn't sustainable for long, it certainly catches the eye of prospective investors.

市场在短期内是投票机,但在长期内是称重机,因此你会期待股价最终跟随每股收益(EPS)结果。因此,有很多投资者喜欢购买每股收益正在增长的公司的股票。让股东欣喜的是,康弘药业在过去三年中实现了48%的年度每股收益复合增长。虽然这种增长率无法长期维持,但它肯定吸引了潜在投资者的注意。

Careful consideration of revenue growth and earnings before interest and taxation (EBIT) margins can help inform a view on the sustainability of the recent profit growth. Chengdu Kanghong Pharmaceutical Group shareholders can take confidence from the fact that EBIT margins are up from 26% to 29%, and revenue is growing. That's great to see, on both counts.

仔细考虑营业收入增长和利息与税前利润(EBIT)利润率可以帮助我们对近期利润增长的可持续性形成看法。康弘药业的股东可以相信EBIT利润率已从26%上升至29%,且营业收入在增长。在这两方面看到这些数据真的很好。

The chart below shows how the company's bottom and top lines have progressed over time. Click on the chart to see the exact numbers.

下面的图表显示了公司的底线和顶线随时间的发展情况。单击图表以查看确切的数字。

big
SZSE:002773 Earnings and Revenue History December 12th 2024
SZSE:002773 每股收益和营业收入历史 2024年12月12日

While profitability drives the upside, prudent investors always check the balance sheet, too.

盈利能力推动上涨,但谨慎的投资者也总是检查资产负债表。

Are Chengdu Kanghong Pharmaceutical Group Insiders Aligned With All Shareholders?

康弘药业的内部人士是否与所有板块的股东保持一致?

Theory would suggest that it's an encouraging sign to see high insider ownership of a company, since it ties company performance directly to the financial success of its management. So we're pleased to report that Chengdu Kanghong Pharmaceutical Group insiders own a meaningful share of the business. Actually, with 39% of the company to their names, insiders are profoundly invested in the business. This should be a welcoming sign for investors because it suggests that the people making the decisions are also impacted by their choices. This is an incredible endorsement from them.

理论上,高内部持股比例是一个好的迹象,因为这将公司的表现与管理层的财务成功直接关联起来。所以我们很高兴地报告,康弘药业的内部人士拥有公司相当可观的股份。实际上,内部人士持有该公司39%的股份,深度投资于业务。这对投资者来说应该是一个良好的信号,因为这表明做出决策的人也受到他们选择的影响。这是他们对公司的一个不可思议的认可。

Does Chengdu Kanghong Pharmaceutical Group Deserve A Spot On Your Watchlist?

康弘药业是否值得列入您的自选?

Chengdu Kanghong Pharmaceutical Group's earnings per share have been soaring, with growth rates sky high. This level of EPS growth does wonders for attracting investment, and the large insider investment in the company is just the cherry on top. At times fast EPS growth is a sign the business has reached an inflection point, so there's a potential opportunity to be had here. Based on the sum of its parts, we definitely think its worth watching Chengdu Kanghong Pharmaceutical Group very closely. Even so, be aware that Chengdu Kanghong Pharmaceutical Group is showing 1 warning sign in our investment analysis , you should know about...

康弘药业的每股收益正在飙升,增长率极高。这种EPS增长水平对吸引投资大有裨益,而且公司内部的巨大投资更是锦上添花。有时,快速的EPS增长是公司达到了转折点的标志,因此这里可能存在机会。根据整体来看,我们绝对认为值得密切关注康弘药业。尽管如此,请注意,康弘药业在我们的投资分析中显示出一个警示信号,您应该了解...

Although Chengdu Kanghong Pharmaceutical Group certainly looks good, it may appeal to more investors if insiders were buying up shares. If you like to see companies with more skin in the game, then check out this handpicked selection of Chinese companies that not only boast of strong growth but have strong insider backing.

尽管康弘药业看起来很好,但如果内部人士购买股票,可能会吸引更多投资者。如果你喜欢看到那些更有投入的公司,那么请查看这份精心挑选的中国公司名单,这些公司不仅拥有强劲的增长,而且有强大的内部支持。

Please note the insider transactions discussed in this article refer to reportable transactions in the relevant jurisdiction.

请注意,本文讨论的内部交易是指在相关管辖区内可报告的交易。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

对本文有反馈?对内容有疑虑?请直接与我们联系。或者,发送电子邮件至 editorial-team (at) simplywallst.com。
这篇来自Simply Wall St的文章是一般性的。我们根据历史数据和分析师预测提供评论,采用无偏见的方法,我们的文章并不旨在提供财务建议。它不构成对任何股票的买入或卖出建议,也未考虑到您的目标或财务状况。我们旨在为您提供以基本数据驱动的长期分析。请注意,我们的分析可能未考虑最新的价格敏感公司公告或定性材料。Simply Wall St在提到的任何股票中均没有持仓。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发